(1) Background: Gastric cancer is a significant cause of cancer-related mortality worldwide. Weight loss and malnutrition associated with cancer are linked with increased mortality rates and reduced quality of life. Cancer cachexia, characterised by the loss of skeletal muscle, is associated with approximately 20% of cancer-related deaths and differs from malnutrition in that it cannot be fully reversed by nutritional support alone. It is now recognised that the primary pathophysiological process underlying cancer cachexia is chronic inflammation leading to increased calorie consumption. Current treatments that focus on nutritional supplementation, psychological counselling, appetite stimulation and reducing inflammation are lacking in efficacy. This review focuses on the evidence supporting the potential roles of natural anti-inflammatory products and their derivatives including fatty acids, probiotics, amino acids, curcumin, fucoidan, epigallocatechin-3-gallate, ginger, resveratrol and Boswellia serrata in the management of gastric cancer cachexia. (2) Results: While natural anti-inflammatory products show promise in a number of in vitro and in vivo studies, there are only a small number of human studies available. Where present, the evidence base is heterogeneous, with varying study methodologies and outcomes. (3) Conclusions: Natural anti-inflammatory products represent a potential adjunctive therapy for gastric cancer cachexia. Further research, particularly well-designed clinical trials, is needed to elucidate their optimal role, dosing and safety profiles in the management of gastric cancer cachexia.
Background: Emergency laparotomy is performed for a wide range of life-threatening conditions and is associated with significant morbidity and mortality. Risk prediction models facilitate accurate communication of operative risk with patients and relatives, in addition to benchmarking unit outcomes. Greater understanding of the impact of sarcopenia or myosteatosis will encourage the adoption of routine radiological reporting of body composition and the incorporation of skeletal muscle gauge (SMG) into risk prediction models. This study investigated the prognostic significance of SMG, an aggregate assessment of sarcopenia or myosteatosis, in patients who had undergone an emergency non-trauma-related laparotomy. Methods: This was a retrospective cohort study of patients aged ≥ 18 years who underwent an emergency laparotomy at the Queen Elizabeth Hospital between January 2014 and December 2020. Body composition and patient outcomes were analysed. Results: In all, 1090 patients with a mean(standard deviation) age of 62.3(17.5) years underwent emergency laparotomy (bowel obstruction, 52.7%; perforation, 26.3%; ischaemia, 9.5%). Overall 30- and 90-day mortality was 10.0% and 11.6%, respectively. On multivariate analysis, low SMG was associated with worse 30- and 90-day mortality, with odds ratios of 2.12 (95% confidence interval (c.i.) 1.18 to 3.83; P = 0.012) and 2.64 (95% c.i. 1.55 to 4.48; P < 0.001), respectively. Low SMG was also associated with an increased length of hospital stay (odds ratio 1.45; 95% c.i. 1.22 to 1.72; P < 0.001). Conclusion: A low SMG was associated with increased postoperative mortality and length of hospital stay after emergency laparotomy. Patients undergoing computed tomography imaging for acute abdominal pain should undergo routine reporting of body composition.